Seventy-five percent of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) who were treated with the antibody ...
Pivekimab Sunirine shows a 75% complete response rate in BPDCN patients in the CADENZA trial, offering new hope for rare ...
Immune Checkpoint Blockade (ICB) has revolutionized the treatment of cancers like melanoma, but up to 60% of patients don't ...
From mutation to medicine: How neoantigen dendritic cell vaccines are reshaping cancer immunotherapy
Overview of the manufacturing process of personalized neoantigen-based DC vaccines. A typical basic process of manufacturing neoantigen-based DC vaccines by using monocyte-derived dendritic cells is ...
Bria-IMT demonstrates a median overall survival of 15.6 months, surpassing historical data for heavily pretreated metastatic breast cancer patients. The therapy is well-tolerated, with no treatment ...
A structurally tuned HPV cancer SNA vaccine boosts CD8⁺ T‑cell responses and slows tumor growth in mice and patient‑derived spheroids, a study shows.
The researchers used lipid nanoparticles (LNPs) to deliver cyclic GMP-AMP (cGAMP) synthase (cGAS) mRNA to cancer cells. This results in production of the endogenous stimulator of interferon genes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results